A Randomized, controlled, open-label trial evaluating the efficacy and safety of chloroquine in the treatment of giardiasis in children

West Indian Medical Journal

Volumn 59, Issue 6, 2010, Pages 607-611

  Canete R ^a   Rivas, D E ^b   Escobedo, A A ^c   Gonzalez M E ^a   Almirall, P ^d   Brito, K ^e  

^a INSTITUTO DE GASTROENTEROLOGÍA   (Cuba)

^b INSTITUTO NACIONAL DE HIGIENE   (Cuba)

^c Academic Paediatric Hospital Pedro Borras   (Cuba)

^d National Centre for Health Promotion and Education   (Cuba)

^e Ministry of Health   (Cuba)

Author keywords

Children; Chloroquine; Giardia duodenalis infection; Metronidazole

Indexed keywords

CHLOROQUINE; METRONIDAZOLE; ANTIAMEBIC AGENT;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; BITTER TASTE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FECES ANALYSIS; FEMALE; GIARDIA; GIARDIASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; TROPHOZOITE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CUBA; FECES; PARASITOLOGY; TREATMENT OUTCOME;

ADOLESCENT; AMEBICIDES; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; CUBA; FECES; FEMALE; GIARDIASIS; HUMANS; MALE; TREATMENT OUTCOME;

EID: 79960952545     PISSN: 00433144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Lasek-Nesselquist E, Bogomolni AL, Gast RJ, Welch DM, Ellis JC, Sogin ML et al. Molecular characterization of Giardia intestinalis haplotypes in marine animals: variation and zoonotic potential. Dis Aquat Organ 2008; 81: 39-51.
2. Buret AG. Pathophysiology of enteric infections with Giardia duodenalis. Parasite 2008; 15: 261-5.
3. Bouzid M, Steverding D, Tyler KM. Detection and surveillance of waterborne protozoan parasites. Curr Opin Biotechnol 2008; 19: 302-6.
4. Mohammed Mahdy AK, Lim YA, Surin J, Wan KL, Al-Mekhlafi MS. Risk factors for endemic giardiasis: highlighting the possible association of contaminated water and food. Trans R Soc TropMed Hyg 2008; 102: 465-70.
5. SterkM, Müller J, HemphillA, Müller N. Characterization of a Giardia lamblia WB C6 clone resistant to the isoflavone formononetin. Microbiol 2007; 153: 4150-8.
6. Müller J, Ley S, Felger I, Hemphill A, Müller N. Identification of differentially expressed genes in a Giardia lamblia WB C6 clone resistant to nitazoxanide and metronidazole. J Antimicrob Chemother 2008; 62: 72-82.
7. Cañete R, Escobedo AA, González ME, Almirall P, Cantelar N. A randomized, controlled, open-label trial of a single day of mebendazole versus a single dose of tinidazole in the treatment of giardiasis in children. Curr Med Res Opin 2006; 22: 2131-6.
8. Escobedo AA, Cimerman S. Giardiasis: A pharmacotherapy review. Expert Opinion on Pharmacotherapy 2007; 8: 1885-902.
9. Gordts B, Hemelhof W, Asselman C, Butzler J. In vitro susceptibilities of 25 Giardia lamblia isolates of human origin to six commonly used anti-protozoal agents. Antimicrob Agents Chemother 1985; 28: 378-80.
10. Baveja UK, Bathia VN, Warhurst DC. Giardia lamblia: in-vitro sensitivity to some chemotherapeutic agents. J Communicable Dis 1998; 30: 79-84.
11. García LS, Bruckner DA. Macroscopic and microscopic examination of faecal specimens. In: Diagnostic medical parasitology. Washington, DC: American Society for Microbiology; 1993: 501-40.
12. Cañete R, González ME, Almirall P, Figueroa I. Infección por Giardia y Giardiasis. Rev Panam Infectol 2004; 6: 39-46.
13. Hollm-Delgado MG, Gilman RH, Bern C, Cabrera L, Sterling CR, Black RE et al. Lack of an adverse effect of Giardia intestinalis infection on the health of Peruvian children.Am J Epidemiol 2008; 168: 647-55.
14. Roxstrom-Lindquist K, Palm D, Reiner D, Ringqvist E, Svard SG. Giardia immunity - an update. Trends Parasitol 2006; 22: 26-31.
15. Wright JM, Dunn LA, Upcroft P. Efficacy of antigiardial drugs. Expert Opin Drug Saf 2003; 2: 529-41.
16. Pérez MA, Cortés LJ, GuerraAP, KnudsonA, Usta C, Nicholls RS et al. Efficacy of the amodiaquine + sulfadoxine-pyrimethamine combination and of chloroquine for the treatment of malaria in Córdoba, Colombia, 2006. Biomedica 2008; 28: 148-59.
17. van Tuyl LH, LemsWF, VoskuylAE, Kerstens PJ, Garnero P, Dijkmans BA et al. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial. Ann Rheum Dis 2008; 67: 1574-7.
18. Basnuevo JG, Sotolongo F. Giardiasis y Aralén (Cloroquina). Rev Kuba 1946; Agosto - Septiembre, 137.
19. Basnuevo JG, Sotologngo F. Tratamiento de la Giardiasis con Arlén-Cloroquina. Rev Kuba 1946; Octubre - Diciembre, 229.
20. BasnuevoJG. La Quinacrina y los nuevos antimaláricos en el tratamiento de la Giardiasis. Rev Cuba 1950; Septiembre - Octubre, 121.
21. Escobedo AA, Núñez FA, Moreira I, Vega E, Pareja A, Almirall P. Comparison of chloroquine, albendazole and tinidazole in the treatment of children with giardiasis. Ann Trop Med Parasitol 2003; 97: 367-71.
22. Busatti HG, Vieira AE, Viana JC, Silva HE, Souza-Fagundes EM, Martins-Filho OA, et al. Effect of metronidazole analogues on Giardia lamblia cultures. Parasitol Res 2007; 102: 145-9.
23. Sadjjadi SM, Alborzi AW, Mostovfi H. Comparative clinical trial of Mebendazole and metronidazole in giardiasis of children. J Trop Pediatr 2001; 47: 176-8.
24. Saffar MJ, Qaffari J, Khalilian AR, Kosarian M. Rapid reinfection by Giardia lamblia after treatment in a hyperendemic area: the case against treatment. East Mediterr Health J 2005; 11: 73-8.
25. Yereli K, Balcioǧlu IC, Ertan P, Limoncu E, Onaǧ A. Albendazole as an alternative therapeutic agent for childhood giardiasis in Turkey. Clin Microbiol Infect 2004; 10: 527-9.
26. Mzayek F, Deng H, Mather FJ, Wasilevich EC, Liu H, Hadi CM et al. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials 2007; 2: e6.
27. Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL et al. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med 2006; 355: 1959-66.
28. Jong EC, Nothdurft HD. Current drugs for the antimalarial chemoprophylaxis: a review of efficacy and safety. J Travel Med 2001; 8 (Sup. 3): 48-56.
29. Santaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications: recognition and management. Drugs 2007; 67: 75-93.
30. Alizadeh A, Ranjbar M, Kashani KM, Taheri MM, Bodaghi M. Albendazole versus metronidazole in the treatment of patients with giardiasis in the Islamic Republic of Iran. East Mediterr Health J 2006; 12: 548-54.
31. Oren B, Schgurensky E, Ephros M, Tamir I, Raz R. Single-dose ornidazole versus seven-day metronidazole therapy of giardiasis in Kibbutzim children in Israel. Eur J Clin Microbiol Infect Dis 1991; 10: 963-5.
32. Bevan CD, Ridgway GL, Rothermel CD. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J Int Med Res 2003; 31: 45-54.